Search the Newsreel

First Tracks Biotherapeutics (TRAX) details $83.9M loss and $168M cash after spin-off

Atara Biotherapeutics 2Q 2026: Revenue $0.63M, Net loss $(9.0)M — 10-Q Summary

Atara Biotherapeutics reported second-quarter 2026 results with revenue of $0.63 million, a significant drop from the previous year, and a consolidated net loss of $9 million for the six months ending June 30, 2026. The company experienced a sharp decline in commercial revenue due …

Atara Biotherapeutics: Q2 Earnings Snapshot

Atara Expects Cash and Cost Cuts to Fund Operations Into Mid-2027

Atara Biotherapeutics announced its second-quarter 2026 financial results, highlighting productive discussions with the FDA regarding the resubmission of its tabelecleucel BLA. The company reported a net loss of $4.8 million for the quarter but expects its current cash, cash equivalents, and short-term investments, combined …

IOVA Stock Price Prediction 2025-2026 | Iovance Biotherapeutics Inc Forecast

Vir Biotechnology (VIR) director restructures 16,000-share holding with Alta Partners fund

Vir Biotechnology, Inc. director Robert J. More reported internal share transfers totaling 16,000 shares of common stock, executed on August 11, 2026. These transactions involved transferring shares held for Alta Partners NextGen Fund I, L.P. (APNG 1) for no consideration in connection with the …

Legend Biotech Shares Fall After Oppenheimer Downgrade

Legend Biotech's shares experienced a decline following an Oppenheimer downgrade from Outperform to Perform, citing potential pressures from competition and a CEO transition. Despite this, RBC maintained an Outperform rating for Legend Biotech, adjusting its price target slightly, due to positive outlooks on Carvykti …

Vir Biotechnology: Astellas Deal Pushes Cash Above $1 Billion And Extends Runway Into Second Half Of 2028

Vir Biotechnology's cash reserves exceeded $1 billion in Q2 2026, extending its operational runway into late 2028, primarily due to a strategic collaboration with Astellas. This deal, involving a $240 million upfront payment and a $75 million equity investment, focuses on VIR-5500 for prostate …

Riot Platforms, Inc. Stock 12‑Month Price Target Raised to $32.52, Implies 68% Upside

Riot Platforms, Inc.'s average stock price target has been increased from $31.28 to $32.52 by 20 analysts, with individual forecasts ranging from $25 to $45. This new target suggests a potential upside of approximately 68% from its August 10 closing price. The consensus rating …

Press Release: Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Bolt Biotherapeutics has released its financial results for the second quarter of 2026. The report includes updates on the company's business operations and its financial performance during this period. Investors and stakeholders can review the full details to understand the company's current standing and …

Legend Biotech (NASDAQ:LEGN) Trading Down 5.3% Following Analyst Downgrade

Acquisition of Own Shares

Lakefront Biotherapeutics NV announced the repurchase of 103,970 of its own shares between August 3 and August 7, 2026, as part of a previously announced repurchase program. The shares were acquired via a discretionary mandate to an independent financial intermediary, with a total value …

LEGN Downgraded by Oppenheimer -- Price Target Lowered to $40.00

Adage discloses 8.38% SAB Biotherapeutics (SABS) ownership in Schedule 13G

Adage Capital Management, L.P. and related entities have reported a beneficial ownership of 8.38% in SAB Biotherapeutics, Inc. (SABS) through a Schedule 13G filing. This stake amounts to 6,405,553 shares, with shared voting and dispositive power, based on 76,464,094 outstanding shares as of May …

Legend Biotech stock downgraded at Oppenheimer (LEGN:NASDAQ)

Oppenheimer downgraded Legend Biotech (LEGN) to Perform from Outperform following the resignation of its CEO, competitive pressures, and reduced M&A prospects. The analyst cited these factors as reasons for the downgrade. Legend Biotech's shares saw a decline on Wednesday after the announcement.

Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?

How Samsara’s (IOT) Operating Leverage Unlocks Margin Expansion

Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Discovery Fund". A copy of the letter is available to download here. Baron Discovery Fund appreciated by 19.08% (Institutional Shares) in the quarter, underperforming the Russell 2000 Growth Index, …

Oppenheimer downgrades Legend Biotech stock rating on M&A concerns

Oppenheimer downgraded Legend Biotech (NASDAQ:LEGN) to Perform from Outperform, lowering its price target to $40 due to diminished M&A prospects, particularly after Johnson & Johnson was removed as a potential buyer. The firm also cited concerns over the CEO's departure, financing issues, and weak …

Lakefront Biotherapeutics (LKFT) swings to H1 2026 profit and tightens cash outlook

Lakefront Biotherapeutics (LKFT) reported a net profit of €16.6 million for the first half of 2026, a significant turnaround from a €259.1 million net loss in H1 2025, primarily due to reduced operating losses and substantial net financial income. The company completed the acquisition …

Green Fresh Biotechnology Narrows Interim Loss on Strong Carrageenan Sales

Zacks Research Upgrades Marriott Vacations Worldwide (NYSE:VAC) to "Strong-Buy"

Zacks Research has upgraded Marriott Vacations Worldwide (NYSE:VAC) from a "hold" to a "strong-buy" rating. This upgrade comes as the company exceeded quarterly earnings expectations, reporting $2.31 EPS against a $1.97 consensus and revenue of $1.32 billion, a 5.9% increase year-over-year. Analysts currently have …

RBC Adjusts Price Target on Legend Biotech to $58 From $59, Maintains Outperform Rating

RBC Capital Markets has adjusted its price target for Legend Biotech (LEGN) to $58, down from $59, while reiterating an Outperform rating on the stock. This revision comes amidst recent news for Legend Biotech, including a downgrade from Oppenheimer and the company reporting its …

Legend Biotech Releases Q2 2026 Financial Results

Legend Biotech (LEGN) reported strong Q2 2026 financial results, with adjusted earnings of $0.16 per share, surpassing estimates. The company generated $387.5 million in revenue, largely driven by its CARVYKTI collaboration, indicating significant growth and market penetration for its cell therapy platform. Wall Street …

Legend Turns Profitable In Q2 As CARVYKTI Sales Jump By 50%

(RTTNews) - Legend Biotech Corporation (LEGN) released financial results for the second quarter ended June 30, 2026. The commercial-stage company turned profitable in the second quarter, compared with a loss in the prior-year quarter, driven by higher collaboration revenue and improved operating income. For …

Legend Biotech (LEGN) Stock Rebounds As Profit Arrives But Carvykti Risk Persists

First Tracks Biotherapeutics Ord Shs (TRAX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Legend Biotech (LEGN) Returned To Profit, Is The Stock Still Cheap?

Precision Trading with Samsara Inc. Class A (IOT) Risk Zones

This article provides an in-depth analysis of Samsara Inc. Class A (NYSE: IOT) with a focus on risk zones and trading strategies generated by AI models. It highlights strong near and mid-term sentiment, a weak long-term outlook, and presents specific strategies for position trading, …

PDS Biotechnology Halts PDS0101 Trial, Pivots to PDS0301 in Colorectal Cancer

PDS Biotechnology has announced the halt of its PDS0101 trial and internal investment, including the discontinuation of the Phase 3 VERSATILE-003 trial, to pivot its resources towards PDS0301. PDS0301, a tumor-targeted IL-12 immunocytokine, will now be the company's lead asset with a priority indication …

Lakefront Biotherapeutics (ENXTAM:LKFT) Stock Reflects Profit Fragility After Revenue Reset

Riot Platforms (RIOT) Stock Jumps As AI Leases Eclipse Mounting Losses

Iovance Biotherapeutics (IOVA) Stock Looks Fairly Valued Despite 222% Returns

Iovance Biotherapeutics (IOVA) stock has seen a significant 221.8% return over the past year, but its current valuation suggests it is now fairly priced rather than cheap. The company scores a mixed 4 out of 6 on Simply Wall St's valuation checks, with a …

What Is Riot Platforms (RIOT) Becoming With Its $9.1 Billion AI Lease?

Why Riot Platforms (RIOT) Is Down 6.1% After Striking a $9.1 Billion AI Data Center Deal

In August 2026, Riot Platforms reported second-quarter 2026 results showing revenue of US$174.24 million but a net loss of US$237.17 million, driven in part by almost US$27.97 million of impairment charges, while bitcoin production rose to 1,587 coins. On the same day, the company …

Legend Biotech (LEGN) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Aug. 11, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Interim Chief Executive Officer - Alan BashChief Financial Officer - Carlos SantosInterim Head of R&D - Yuhong QiuDirector of Investor Relations - Caroline LeCates Paul TAKEAWAYS Worldwide Net …

Avecho Biotechnology Cuts Shareholder Numbers via Small Holding Sale Facility